Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's one heck of a typo. Actually that goes way beyond a typo. Makes you wonder about the person's motivation...
Investors losing money by reacting to the bad journalism are going to be irked to say the least.
Agreed.
Independence Energy (IDNG) a few monthes ago was an oil and gas company who bought into some depleted wells just as oil and gas went into a bear market. Brilliant! Now, dumping that for a loss, they've transformed themselves into a me-too wannabe thermometer reseller trying to jump on the ebola bandwagon. IDNG overextended themselves with their previous debacle now,apparently have zilch abilty to raise capital, convertable or otherwise. They have no distribution channels anyway and no experiance in the medical sector. I wouldn't touch IDNG with a ten foot pole.
SIMH is like Fort Knox gold compared to IDNG, imo.
It looks like the vascular "stop-leak" drug they tried may have blocked the hemopure viral attractors from working. Maybe like throwing talcum powder on sticky-tape - it doesn't stick anymore.
Reading through again, it could be inferred that Zmab is an older version, perhaps a sort-of predecessor, the state of the tech having moved on to Zmapp. Which could be why they had to rummage around in the back of the freezer, so to speak, and dig it out of cold storage.
Might not be a typo as first appears.
Evidently, there also is a similar antibody based one called Zmab (made from mice). It was never tested on humans yet so not known whether it is safe. Maybe they ran out of Zmapp and decided to try the Zmab since his condition being so dire it outwayed the risks, though it tragically ended up being too late by the time they got it anyway. The only test so far was on monkeys given within 24 hours of exposure, so it might not be as effective as Zmapp, but maybe they had no alternative.
ZMAb
ZMAb is a mixture of three mouse mAbs: m1H3, m2G4 and m4G7.[2] A study published in November 2013 found that EBOV-infected macaque monkeys survived after being given a therapy with a combination of three EBOV surface glycoprotein (EBOV-GP)-specific monoclonal antibodies (ZMAb) within 24 hours of infection. The authors concluded that post-exposure treatment resulted in a robust immune response, with good protection for up to 10 weeks and some protection at 13 weeks.[14]
ZMab was created by Defyrus, a Toronto-based biodefense company, funded by the Public Health Agency of Canada.[15] The identification of the optimal components from MB-003 and ZMab was carried out at the Public Health Agency of Canada's National Microbiology Laboratory in Winnipeg.[16]
http://en.wikipedia.org/wiki/ZMapp
re: "Which Canadian MMPR Is Superior?
Wait. Wait. Oh, I know... SPRWF
Well, it is "Superior" :)
(actually I really like tweed, but have a little of that too...)
oops I remembered wrong -- "Supreme"
Well that's close though, isn't it.
Kind of means the same thing...
I think after being cured by serum , then there would be a follow-up vaccination.
Years ago I visited some relatives who had a farm and drank unpastuerized milk. And what do you know, it does taste better. In this case, I knew where it was coming from, even to the point of having made acquaintance with the cow. On the other hand, just going out and getting unpastuerized milk from anywhere, there could be a risk factor. If I were a patient with a comprimised immune system, the unproven risks and apparent diminished esthetics of pasterurization, cold or otherwise, might outway the risk of picking up something worse from a "raw", albiet natural, product. As long as both kinds would be available, it doesn't seem like it would be a big problem for potential customers since people could still make their own judgement. It sounds like you have gotten pretty good at growing and are understandably feeling beleagured by the political situation. On a bit of a crusade, one might say.
In case you get tired of the present crusade, and may want to add a new one, get a load of this:
(and here you thought cold pasteurization was bad...)
http://pixelusmaximus.com/gazelle/monsanto-is-creating-gmo-marijuana/
And the sun might explode. Yes. <g>
Where I work we utilise machine mounted high-end industrial units made by RayTek that go for around $4500 each, to monitor the temperature of steel billets going into a forging operation. If the temperature is wrong, it can wreck the press, screw up expensive tooling and/or produce bad parts. I tried aiming one at myself and it read about 80 degrees, way off. That's because they have to be ordered for a specific material and range with the right sensing element and optical filters installed. In this case 1000 to 2500 degrees. There is also a thing called emissivity which depends on the surface characteristics of the object being measured that needs to be calibrated for. I noticed a utility hand-held by Fluke appearing in the ad section next to the messages area on this board. Here again, Fluke makes good instruments (especially meters) but the gun type depicted is made for measuring pipes and electric motors, not medical use.
I bought a cheap meter to use on my car and thought there was something wrong with the voltage regulator until I rechecked using a decent meter. There are a lot of cheap thermometers for general use that, here again, like a cheap meter, could end up wasting time and money. If it's unreliable for medical screening it could cost lives.
Out of dozens of thermometer brands, there are only a few models that are going to be comparable. The design of the caregiver looks like it is more comfortable to use than the boxy other one I saw, which is probably one reason why it enjoys wide customer acceptance in its intended market.
This board was never very active so haven't looked, posted for a while. Sorry, I got out around .04 a while back.
Initially this looked pretty good, but the landscape has changed. You may have noticed that oil dipped below $80 a barrel, it's now below $60, I believe...
This means that all the alternative energy stuff is not so urgent now. There isn't going to be as much demand for hybrids, electric cars i.e. lithium batteries.
I also emailed the co. with some suggestions but they never got back with me, so, lost some enthusiasm there.
fwiw I am pretty much out of resource stocks, and have largely redeployed into certain Canadian med mj stocks and ebola plays. I'm not suggesting anything, but simh is at a similar pps right now...
Maybe Time pulled it out of embarrassment. The gist of the article was that many of the people Time picked for recognition were little more than self-serving celebrities, whereas people fighting ebola were actually making a contribution to humanity, improving the human condition, and were much more deserving of recognition.
eek! me too.
Just checked.
There was zero volume today on the actual otc exchange, but mm are still there on level 2. The Canadian exchange shows GHG trading today - volume of 65,000 shares.
I think it's just scottrade. Probably need to call them if it doesn't clear up. The streaming quotes has also been showing 0.05 on the bid incorrectly for a while now too. Some kind of glitch...
[..] SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today announced that it has initiated a relationship with Kentucky Bioprocessing LLC to establish processes to support large-scale production of the active affinity agents immobilized within the Aethlon Hemopurifier . Such affinity agents allow the Hemopurifer to selectively capture a broad-spectrum of viruses from blood and other fluids. The Hemopurifier is the first-in-class medical device to selectively adsorb viruses and immunosuppressive particles from the bloodstream. [..]
http://aethlonmedical.investorroom.com/index.php?s=43&item=30
I think I read something similar somewhere else but don't remember where. I read through a lot of stuff actually. The gist of what I have read though, and what you can infer from the above is that they have just begin taking the first steps toward large-scale production. One would expect they are progressing and looking into available options, but it's going to take more time before they can make more than a few hundred at a time, if even that many.
Obviously, the inert plastic containers shouldn't be an issue. They are probably a somewhat standard off-the-shelf item. But the stuff inside, the micro-tubular matrix and lining it with (e.g. immobilizing) the complex molecular compound that the virus's are tricked into sticking to, are going to have to pass through the next stage of technical development to translate what is probably currently, a more-or-less a small scale lab environment, to designing an actual mass production process capable of making thousands, or, dare I say, millions...
re: you have to find a broker that shorts, and you usually need a deposit of 30k or more ...
Name one. I don't know of any retail brokers that offer it.
One of the news pieces they mention that they are looking into commercial production... i.e. It's not in commercial production yet. What they have looks like only prototype quantities. They would not able to fill a large order (yet).
Plus the medical community at large is only now starting to become aware of its existence. Many of them probably blow it off, mistaking it as a simple filter. Plus the pharmacology approach remains the main paradigm. Devices are outside of that and only get secondary consideration. But, because it works, acceptance will be inevitable. imo.
I have little doubt that demand will grow and hopefully coincide with an increased ability to keep pace at producing them. Furthermore, Ebola is just a fraction of the application spectrum.
I guess the question would be, can Double-stranded RNA Activated Caspase Oligomerizers be mass produced at reasonable cost? And salient to this board, would they lend themselves to plant based production methodology?
Wonder if anyone at IBIO has seen the article?
Active Component Of Cannabis Can Regrow Brain Cells:
http://www.collective-evolution.com/2014/12/01/active-component-of-cannabis-can-regrow-brain-cells/
At least it's news. Even if not the news we are all waiting for yet. It's not excessive. I imagine there are legal expenses that need to be covered and so forth. I seem to recall that the co. isn't mired in toxic loans so it is actually good that they are going the equity route, imo.
makes sense.
It's a new enterprise, one has to expect some delays here and there. I'm already in a highly successful, rapidly maturing one, but I thought I'd get in on this one early. I like what they have planned so far, kind of reminiscent of star-trek.
i have no such problem with scottrade
Assuming you already have some and want to add, i think a good strategy would be to pile a large part of your intended order on the bid. this gives the mm competition to cover which they normally do at the bid. Then ping the ask. they will still sell at the ask, (naked) short shares if they are out of inventory, but if it starts to look hard to cover with a large order on the bid that is not theirs, this might give them pause and they will allow the ask to go up. Then you creep your bid up. if the bid gets taken out, well you were going to buy some anyway...
Well, at least there is some rationality over there. I suppose that we should have expected the legal process to take a lot of time. It looks like another potential barrier has fallen. I wonder how many barriers remain? There can't be too much now.
If that's the interview where he mentions that they didn't have trouble finding drill rigs, anyway, one of the interviews, that prompted me to reflect on, that, just a few short years ago, drill rigs, resource equipment and services were at a premium. Now that the resource sector is at low ebb, building the mine will likely be able to be achieved at lower cost. Therefore, using projections based on costs from when resource extraction was booming aren't an accurate way to predict mine completion costs. The time to buy an air conditioner is in the winter. I think the timing as events progress will continue to be favorable.
Here's something interesting from the AEMD board.
I haven't read all the recent IBIO msg so I don't know if somebody may have posted this already...
[ref:aemd, ihub msg#9038]
"We have two manufacturer agreements that I know of with one in Europe and another with a company in the south (Kentucky). It is a plant based lectin made from tobacco plants. I do Forster a shortage as growing aggie can be ramped up in short order."
So, the two frontrunner treatments use ingrediants that can (best) be made by the IBIO process.
Yes,there is value here. On resource plays,this period between discovery and production is what I like to call the long dark teatime of the soul (with apologies to Douglas Adams ). In this case I don't think it will be very dark or extremely long. Eventually, I think this will be comparable to a nice mining co. like stillwater.
Somebody probably put a market order in on low volume. I've seen it happen. but not this extreme...
Are we millionaires? I wiah it were true. My scottrade shows over $5000 sh. too<?!> It's got to be some kind of glitch. isn't it?
The person in the last report was saved by blood serum via a blood transfusion that contained antibodies. Another guy wasn't so lucky as he had the wrong blood type - didn't match. But that's what ZMapp is, a serum containing the active ingredients of the antibodies. And it's blood type neutral. The thing is, with a serum, you need a lot of it to work as compared to a vaccine which is a smaller dose to get the immune systom tuned in to the particular virus. if the immune system is already overwhelmed, which ebola is adept at, you need serum , which is where the IBIO process comes in.
The administration has directed major news media to not report incidents of ebola exposure. News people are complying with the "request" likely because they don't want to lose privledged access via the white house press corps, so it stops short of actual censorship. But, this is why ebola has subsided from the news and the purpose of reducing public "hysteria" seems to be working somewhat, evidenced by the posters here thinking that ebola is "over". In fact, it is still running rampant in africa, cases were up over 30% - 13,000 at last count. A lot more people are being "monitored" outside africa, you just won't see it in headlines any more...
me too (scottrade). just added 20k yesterday, in fact...
No, but they always stop going down. Eventually.... :)
Ucore's play is on an icy barren island with no infrastructure whatsoever. I think the Alaska state infrastructure loan money is for just roads, docking for ships, hot dog stands, that sort of thing. I actually had some, but dumped it when they said that they were going to rebury the uranium, which would have been salable product. Anyway we already have roads
re: I'm canadian and I know I would never use tweed or any other MMJ licensed provider. Why bother when I can get it way cheaper on the black market?"
Um... Because the clinically grown irradiated product is certified to be 100% oregano, pesticide, battery acid, bug, bacteria, mold and ebola free? Just guessing...
Looks like there is good reason why ZMapp is considered "the most promising candidate so far".
[...]
"Two other small U.S. biotech companies, Chimerix (CMRX) and Mapp Biopharmaceuticals, are working on "antiviral" treatments for Ebola.
Thomas Duncan, the first person diagnosed with the disease on U.S. soil, was treated with a drug called Brincidofovir, made by Chimerix. He did not survive.
Patients at Emory University in Atlanta appear to have been helped by ZMapp, an experimental drug made by Mapp Biopharmaceutical. "
[...]
http://money.cnn.com/2014/10/28/news/companies/ebola-drug-billion/index.html
re: "Where are all those shares coming from. The only way they could get all those shares is if IBIO pints them. Why, who knows. "
No they're not. They're being "printed" by a high roller with market maker trading privileges. I would estimate, over 90%, anyway. A market maker can sell as many pseudo shares as he wants, "to provide liquidity" - which is why they get to do that. This is also called "naked shorting" - there are no actual shares being borrowed and sold. He only has to indicate that he knows where to get them (can you guess where). They have 14 days, according to the rules, otherwise, they get slapped ( lightly on the wrist, at least, historically) with a "failure to deliver". They still don't have to cover though.
A retail short position over $5 has to involve actual borrowed shares and you get charged interest, like on any loan, so there is a string incentive to cover at some point, but the high roller with mm power doesn't have the same constraints.
As a retail US investor, I'm not allowed to short stocks with a pps under $5, so, the ridiculously high volumes going down are not from retail. A typical agenda for the high roller/hedge fund (perhaps with loan shark cohorts) is to drive a small indebted company into bankruptcy, in which case, they never have to cover. Also possible, if the company is a target for hostile takeover, it is way to get to get a big discount on the share price ahead of time.
Another thing possibly indicated by ridiculously huge volumes is a "walk-down" wherein , basically, the left hand (of basically the same entity) sells to the right hand, then vice-versa, adjusting the pps as they go. With an occasional dump to hammer down a pesky bump here and there. It doesn't cost them any money, they've already got a bundle of cash from selling all the naked short shares going into the national crisis news generated public speculative interest peak.
The reason bashers appear is to destroy "good will" - which is an actual accounting entry based on public perception of future pps performance, or, in other words, to create a "good will impairment", the goal of the negative publicity. Retail generally can't stop the process, but they can muck up the operation a bit, which is why they are being attended to by the minion trolls, on the various message boards, while the naked shorting swamps out the remaining calculated retail volume.
If we're lucky, it may be that it may be a more simple form of manipulation and it will be allowed to run again at some point, which is possible, given that the company is likely to do very well in the upcoming climate of developing events.
I saw that pr also from the "competition" NG.. too. If you read it carefully and critically, it could also and probably means that they put in an order to have 3000 built total(which is probably all the money they could scrape together) and a partial of that that will be shipped.and at that, probably to a distributer , (no actual big customer named)
re:"this mandatory quarantine for DR's and medical folks is not a good thing, it will stop DR's from going there to help ........ JMO
They need to appropriate a nice hotel, or at least a decent hotel, with room service (presumably delivered by people in hazmat) Then people wouldn't mind so much or might even look forward to it...
Not enough hamsters?
[...]
"
Sanofi, whose Sanofi Pasteur division is the largest supplier of flu vaccine in the U.S., says it delayed shipments of certain forms of the flu vaccine Fluzone because one of the flu strains used to produce the shot grew more slowly than expected. Shipments of three versions of Fluzone are expected to continue into November, including adult and pediatric versions of a vaccine targeting four flu strains, as well as a shot that targets three flu strains.
The company still plans to produce all of the 65 million doses it has projected for the U.S. market this season, a spokesman said.
GlaxoSmithKline has reduced its production target for the U.S. market to a range of 26 million to 27 million doses, from a prior forecast of 28 million to 33 million doses, a spokesman said. The company delayed shipments of a portion of its vaccine supply because batches made at a plant in Ste-Foy, Quebec, didn't meet Glaxo's quality-assurance standards and were discarded, a spokesman said.
In June, the U.S. Food and Drug Administration sent a warning letter to GlaxoSmithKline, saying the Quebec plant had deviated from manufacturing rules in its production of the flu vaccine Flulaval. FDA inspectors cited microbial contamination in the plant, among other findings. The FDA urged GlaxoSmithKline to work closely with the agency to correct the problems, "given the potential contributions of Flulaval to the public health."
[...]
http://ih.advfn.com/p.php?pid=nmona&article=64166264